Radiolabeled Phospholipid Ether Analogs for Dual Modality Tumor Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current imaging techniques for tumors, such as CT and MRI, are limited in providing conclusive diagnoses due to their inability to offer functional or biochemical information, while nuclear medicine techniques like PET and SPECT rely on radiopharmaceuticals with limited specificity for tumor localization, leading to inaccurate detection and characterization of malignant tissues.
Innovation Solution
The development of radiolabeled phospholipid ether analogs, specifically 124I-18-(4-iodophenyl)-octadecylphosphocholine (NM-404), which are selectively retained in malignant tumor cells due to their inability to be metabolized, allowing for both diagnostic imaging and therapeutic applications through hybrid CT/PET scanning.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of information
If conventional imaging techniques (CT, MRI) are used for tumor detection, then anatomical information is obtained, but functional or biochemical information is not provided
Solution Approach 1:
The patent combines CT and PET imaging modalities into a hybrid CT/PET scanner that simultaneously provides anatomical (CT) and functional (PET) information. The radiolabeled phospholipid ether analogs are administered to patients, and the hybrid scanner detects both the anatomical structure via CT and the metabolic activity via PET, eliminating the need for separate imaging sessions and providing comprehensive diagnostic information in one system.
Solution Approach 2:
The radiolabeled phospholipid ether analogs serve multiple functions: they act as both diagnostic agents for PET imaging and potential therapeutic agents. The same compound that provides functional imaging information can also be used for treatment, particularly in radioimmunotherapy applications, making the system universally applicable for both detection and treatment planning.
2Loss of information
If nuclear medicine techniques (PET, SPECT) are used for tumor detection, then functional information is obtained, but specificity for tumor localization is limited
Solution Approach 1:
The phospholipid ether analogs exhibit selective accumulation in malignant tumor cells due to their unique metabolic characteristics. Tumor cells have altered phospholipid metabolism and cannot properly metabolize these analogs, causing them to accumulate specifically in tumor tissue rather than normal tissue. This provides localized, tumor-specific imaging signals that improve both detection accuracy and characterization capability.
Solution Approach 2:
The patent uses radiolabeled phospholipid ether analogs that undergo specific metabolic changes in tumor cells. The analogs are designed to be retained by tumor cells through their inability to be metabolized, creating a distinctive metabolic signature that differentiates tumor tissue from normal tissue. This metabolic parameter change provides superior tumor localization specificity compared to conventional radiopharmaceuticals.
3Speed
If radiopharmaceuticals with short half-life (e.g., 18F-FDG) are used, then rapid imaging is possible, but distribution and versatility are limited
Solution Approach 1:
The patent employs radiopharmaceuticals with varying half-lives depending on the specific isotope used (e.g., 18F, 64Cu, 89Zr, 124I). This allows optimization of the half-life parameter based on the specific application requirements - shorter half-lives for rapid imaging when needed, and longer half-lives for distributed delivery and therapeutic applications. The same phospholipid ether analog platform can be labeled with different isotopes to match different clinical scenarios.
Solution Approach 2:
The phospholipid ether analog platform is universally applicable with multiple radionuclides, enabling both diagnostic imaging and therapeutic applications. The same molecular structure can be labeled with different isotopes for PET imaging, SPECT imaging, or radioimmunotherapy, providing a versatile system that adapts to different clinical needs without requiring separate agent development.
4Speed
If FDG is used for PET scanning, then rapid imaging is possible, but selectivity for tumor cells is poor due to metabolism in normal tissues
Solution Approach 1:
The phospholipid ether analogs are specifically retained by malignant tumor cells due to their unique metabolic characteristics. Normal cells can metabolize these analogs properly, while tumor cells with altered phospholipid metabolism cannot, causing selective accumulation in tumor tissue. This creates a localized imaging signal that is specific to tumor cells, improving both sensitivity and specificity for tumor detection and characterization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
NM-404 enables accurate non-invasive detection, characterization, and treatment of malignant tumors by providing both anatomical and functional imaging, distinguishing benign from malignant tissues and monitoring treatment response with high specificity and prolonged retention in tumor cells.
Implementation Method 1
selectively retained in malignant tumor cells due to their inability to be metabolized
Implementation Method 2
radiolabeled phospholipid ether analogs, specifically 124I-18-(4-iodophenyl)-octadecylphosphocholine (NM-404)
Data Source
AI summary
The present invention provides agents and methods for dual modality virtual colonoscopy that gives both anatomical and functional information using hybrid CT/PET scanning. In preferred embodiments, the present invention provides radiolabeled tumor-specific agents and methods for distinguishing benign polyps from malignant tumors. In further embodiments, the present invention provides compositions and methods useful for distinguishing morphological and functional subregions of a selected region of tissue based on relative levels of phospholipid metabolism. Preferred radiolabeled tumor-specific agents are phospholipid ether analogs labeled with a halogen radioisotope. In certain preferred embodiments, the compositions including radiolabeled phospholipid ether analogs have therapeutic actions in addition to functionally identifying malignant tissue.